For those of us still following the progress of Cavatak, Merck is presenting the results of the KEYNOTE 200 trial at ESMO18 on the 20th Oct.
LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
Presentation Number LBA40
Lecture Time17:15 - 17:15
Speakers Charles M. Rudin (New York, US)
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=lba40
- Forums
- ASX - By Stock
- VLA
- what is merck doing with cavatac
what is merck doing with cavatac, page-3
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)